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Abstract
Objectives: Smell/taste disturbances are a common but underrated, under- researched 
and under treated sensory loss and an independent risk factor for reduced longevity. 
This study aimed to characterise the experience of patients with these disorders in 
seeking help.
Design: The study was designed by patients together with clinicians through a dedi-
cated workshop and conducted as a cross- sectional survey to capture experiences in 
public and private healthcare settings internationally.
Setting: Primary, secondary and tertiary care.
Participants: Any members of the public self- reporting a smell/taste disorder were 
invited to participate.
Main outcome measures: The survey captured information including experience 
of getting consultations and referrals to medical professionals, treatments offered, 
costs incurred and related problems with mental health.
Results: Of 673 participants; 510 female, 160 male, three not stated, self- reported 
aetiology included sinonasal disease (24%), idiopathic (24%) and post- viral olfactory 
dysfunction (22%); true gustatory disorders were typically rare. Failure of medical 
professionals to recognise the problem was a key concern - 64%, 76% and 47% of 
GPs, ENT specialists and Neurologists acknowledged, respectively. Other issues in-
cluded repeated ineffective treatments, difficulties getting referrals to secondary/
tertiary care, mental health problems (60%) and a mean personal cost of £421 to 
seeking advice and treatment. Whilst the participants were self- selecting, however, 
they do represent those who are seeking help and intervention for their disorders.
Conclusion: There is an unmet need for these patients in accessing health care in-
cluding a clear need to improve education of and engagement with the medical pro-
fession in Otorhinolaryngology, General Practice and other specialties, in order to 
remove the current barriers they face.
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1  | INTRODUC TION
1.1 | Background and rationale
Smell is the forgotten sense; even when facing a problem with their 
sense of smell, patients often struggle to get recognition, let alone 
diagnosis or treatment from healthcare professionals. Based on com-
parative data from the Royal National Institutes for the Blind and the 
Deaf, olfactory disorders are as common as profound hearing loss 
and blindness affecting an estimated 5%- 20% of the population.1 
Common causes of olfactory disorders include chronic rhinosinusi-
tis, post- viral olfactory loss and post- traumatic olfactory loss2 as well 
as it being present in the majority of cases of Parkinson's disease and 
common in Alzheimer's disease.3 We have also witnessed the rise of 
sudden onset anosmia as a marker of COVID- 19 infection caused by 
the SARS- CoV- 2 virus.4- 11 It remains to be seen how many new cases 
of lasting olfactory loss will arise from those afflicted by the pan-
demic, but it is possible that over 6 million people globally now have 
symptoms that last beyond 4 weeks based on WHO infection rates.
Recent population studies have now identified anosmia as an in-
dependent risk factor for shortened longevity, even after controlling 
for dementia and cardiovascular disease.12- 15 It is not clear why this 
is so but may suggest that the olfactory system acts as a barom-
eter of environmental impact on the central nervous system as a 
whole. As this phenomenon has been observed in several countries 
it clearly demonstrates that olfactory disorders deserve to receive 
greater attention than they currently do.
Taste is often thought to be lost by those affected by olfac-
tory disorders due to the misperception of retronasal olfaction as 
a “taste” sensation. In reality only a small percentage of people re-
porting a problem with their sense of smell or taste experience a true 
gustatory disorder, but due to this common misperception alongside 
the need to be representative of all patients with chemosensory dis-
orders, it is always important to encapsulate both senses within any 
work of this kind.
Fifth Sense, the UK charity for people affected by smell and taste 
disorders, was founded in 2012 when authors DB and CP met and 
agreed on the need for patient advocacy to tackle the unmet needs 
of patients affected by olfactory disorders. Since then, with the help 
of a growing membership, we have been able to characterise the sig-
nificant impact of olfactory disorders on those affected16,17 and we 
have also become aware of the frustrations many members in their 
attempts to seek medical help and getting their sensory loss taken 
seriously.17- 19 In 2019, Fifth Sense was awarded a National Lottery 
Grant for £238 815 to enable it to develop and grow its work, includ-
ing the establishment of a network of patient support hubs.
1.2 | Objectives
Following on from the above, this study aimed to characterise 
the details of the difficulties faced by patients with olfactory and 
gustatory disorders in accessing health care as a patient and public 
co- production.20
2  | MATERIAL S AND METHODS
2.1 | Study design
The study was designed as a cross- sectional survey of the experi-
ence of people affected by olfactory disorders in accessing medi-
cal care. A survey questionnaire was developed using a focus group 
meeting of the public, patients and clinicians (Figures 1 and 2). The 
survey was then set live online and ran for 16 weeks. It was promoted 
via social media internationally. As the survey was anonymous and 
considered to be service evaluation, there was no ethical approval 
sought in line with the Health Regulation Authority guidance: http://
www.hra- decis ionto ols.org.uk/resea rch/docs/Defin ingRe searc hTa-
ble_Oct20 17- 1.pdf.
2.2 | Setting
The survey was open to anyone globally with access to the world 
wide web and declaring themselves an affected individual and 
was promoted through social media channels including the Fifth 
Sense website, and its Facebook and Twitter accounts. The 




All members of the public self- reporting a loss or dis-
turbance of olfaction and/or gustation were entitled to participate 
in the survey.
Keypoints
• Smell/taste disorder patients have difficulty getting 
their disorder recognised.
• Key problems are a lack of onward referral and repeated 
ineffective treatments.
• Neurologists are least likely to acknowledge their 
disorders.
• Mental health problems secondary to their disorder are 
very common.
• Patient engagement in research priorities is critical and 
being addressed through a Priority Setting Partnership.
     |  3BALL et AL.
2.3.2 | Sources and methods of selection of 
participants
Survey participants were able to access the survey themselves free 
of charge via the web- based platform SurveyMonkey. Participants 
were self- selecting and could participate from any country 
internationally.
2.4 | Data sources/management and variables
The survey asked for basic demographics including age and sex. 
Participants were asked to declare the underlying cause for their 
smell loss. Further questions explored participants use of medical 
services, costs borne in doing so and any resistance encountered. 
See Appendix 1 for details.
2.5 | Bias
We aimed to reduce bias in responses by making the survey widely 
available but inevitably, those who are not online or have access to 
the aforementioned social media would not have seen this oppor-
tunity. Although the survey was initiated in the UK and Fifth Sense 
membership is predominantly UK based, the international availabil-
ity aimed to derive a broader healthcare view across other health-
care systems.
2.6 | Study size and statistical methods
As this was an exploratory study, no sample size was set. Due to the 
nature of the study, descriptive statistics only have been utilised in 
reporting the survey data.
3  | RESULTS
3.1 | Participants
A total of 673 participants recorded information on the survey dur-
ing the study period. Not all 673 participants responded to every 
question, so percentages below are expressed with the total number 
of responses as the denominator. For reference, there are currently 
3000 people registered as members of Fifth Sense.
3.2 | Descriptive data
Of the 673 participants, 510 were female and 160 were male; three 
preferred not to state their gender. The age of participants ranged 
from 10 to 88, with a mean age of 56 and a mode age of 63. The 
geographic distribution of participants can be seen in Figure 3 with 
469 (70%) reporting their location as being in the UK. The aetiology 
reported for participants can be seen in Figure 4 with 28% report-
ing chronic rhinosinusitis, allergic rhinitis or Aspirin/Non- Steroidal 
Exacerbated Respiratory Disease (A/NERD) and 25% reporting post- 
viral olfactory loss (PVOL). The range of duration of reported olfac-
tory disorders was 1 month to 67 years with a mean of 13 years and 
a mode of 2 years.
3.3 | Main results
3.3.1 | Recognition of the olfactory disorder as a 
significant problem
Getting recognition from doctors that their condition is a significant 
problem for them was challenging for some participants, with 64% 
reporting that their GP positively recognised their disorder and 76% 
reporting recognition by an otorhinolaryngologist; for those who 
had seen a neurologist, only 47% reported that they felt their dis-
order had been recognised and for those seeking a private specialist 
opinion, 66% (Table 1a- c).
3.3.2 | Prescription of treatment
In primary care, 195 respondents (40%) reported receiving a pre-
scription related to their olfactory disorder. In secondary care, 
respondents reported receiving a prescription from 54% of otorhi-
nolaryngologists and 10% of neurologists, respectively. For those 
who sought private consultations, 46% reported receiving a pre-
scription. Repeated treatments were reported from 31% of GPs 
to 37% of otorhinolaryngologists. In terms of effectiveness of the 
treatment, 8% of GP prescriptions, 23% of ENT prescriptions, 2% 
F I G U R E  1   Workshop in progress— Group discussions between 
participants, Fifth sense members, clinicians, researchers and 
artists to expand on the themes of the day— “mapping the 
patient journey & its challenges”
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of neurology prescriptions and 20% of private prescriptions were 
deemed by the patients to have helped improve their sensory deficit.
3.3.3 | Useful information and advice
In primary care, only 7% felt that they received useful information 
and advice, with a rise to 33% for ENT and 13% in neurology in sec-
ondary care and in the private sector only 28%.
3.3.4 | Healthcare consultations
The range of reported GP consultations for respondents was 0– 150 
with a mean of 5.8 and a mode of 1. In Otorhinolaryngology, the 
range was 0– 75 with a mean of 4.6 and a mode of 1. For Neurology, 
this was much lower with a range of 0– 54 and a mean of 0.9, and 
similarly, in private health care, the range was 0– 50 with a mean of 
1.7. Seventy- one per cent of respondents reported being able to get 
a referral to Otorhinolaryngology and of these 34% were given a 
choice of location but only 20% a choice of specialist. Information 
from the Fifth Sense website informed 29% to guide their choice of 
referral centre with 54% having to request the referral themselves 
and 59% stating they felt their case was recognised as needing a 
referral. Only 4% of respondents reported having their case declined 
by their local Clinical Commissioning Group but 40% felt that Fifth 
Sense information had helped the process of getting medical advice.
3.3.5 | Travel and cost of healthcare appointments
Respondents were asked to estimate how far they had travelled in 
miles to seek information or treatment for their disorder and re-
ported a range of 0 to 15 250 miles with a mean of 200 miles and a 
F I G U R E  2   “Customer journey”— 
workshop activity
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median of 30 miles. The personal cost of doing so showed a range of 
£0- 41 100 (highest figure in USA) with a mean of £421 and a median 
of £50. When analysed further by country, the USA has the highest 
mean cost per respondent at £2277, followed by Australia, Canada, 
United Kingdom and New Zealand (Table 2).
3.3.6 | Improvement and treatment impact
Only 138 respondents reported an improvement of their disorder 
with 89 (17%) saying they felt as if this was the result of medical ad-
vice and/or treatment and 59 (11%) who felt that it was in response 
to smell training.
3.3.7 | Quality of life including mental health
All but 14 respondents reported an impact on their quality of life with 
60% reporting either anxiety and or depression as a consequence of 
their sensory loss. Specific treatments reported included 102 taking 
GP- prescribed antidepressants/sedatives/anxiolytics (15%), 42 tak-
ing over the counter remedies (6%), 73 receiving counselling (11%) 
and other alternative therapies used included acupuncture, mari-
juana use and meditation (4%).
3.3.8 | Overall patient perspective
An open comments section was included to supplement the quan-
titative data that provided some important insights from our par-
ticipants' perspectives. The quotations were chosen by our patient 
co- authors as representative of the typical experiences.
1. It is not really taken seriously. The attitude is almost “Well, 
at least you are not deaf or blind.” The effect on my daily 
life is not recognised.
2. I am low in mood. I hate eating and don't feel hungry. It affects my 
job and makes me feel unsafe from fire and gas leakages.
F I G U R E  3   Geographic distribution of 
survey respondents
F I G U R E  4   Aetiology of respondents
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3. I feel that even ENT specialists do not see this problem which 
truly affects your quality of life as even a problem.
4. Feel like it's minimized by people and professionals who think it 
must be nice not to smell kids' dirty nappies or that you're only 
missing out on smelling flowers and cookies in the oven. It is a real 
issue - gas hob, smoke, taste diminishes, lack of shared experience 
with family, and memories compromised.
5. Following treatment, I am able to smell again much of the time. 
It is so wonderful to be able to smell the ocean, to smell coffee 
brewing, to smell bacon or onions cooking. I can smell my hus-
band's skin, or the soap he last used. I can smell the soap I use in 
the shower, which never ceases to amaze me. I can smell whether 
fruit is ripe or not. This is all incredibly wonderful, it adds such a 
richness to your life. Not to mention: I can smell gas, if the burner 
on the stove didn't turn on correctly, or paint, if a hallway is newly 
painted. I can smell if milk has gone sour. If I can smell these things 
I can protect myself from them better.




Have you been seen by a
GP? 507 (95) 27
ENT specialist? 444 (87) 68
Neurologist? 112 (34) 221
Private provider? 130 (40) 199
Have they recognised your smell/taste disorder is a problem to you?
GP 319 (64) 178
ENT specialist 304 (75) 104
Neurologist 58 (47) 66
Private provider 99 (66) 50
Have you been prescribed any treatment?
GP 195 (40) 293
ENT specialist 238 (54) 199
Neurologist 11 (9) 114
Private provider 69 (47) 78
Have they provided you with any useful information or advice about 
your condition?
GP 35 (7) 456
ENT specialist 149 (33) 298
Neurologist 17 (13) 111
Private provider 41 (28) 107
Have you been prescribed the same treatment by them on more 
than one occasion?
GP 123 (31) 269
ENT specialist 131 (37) 223
Neurologist 2 (2) 85
Private provider 34 (28) 86
Has any treatment prescribed by them improved your sense of 
smell/taste?
GP 30 (8) 349
ENT specialist 81 (22) 270
Neurologist 2 (2) 90
Private provider 25 (20) 99




Have you been referred to an ENT Specialist 
by your GP/Neurologist?
389 (71) 158
Were you given a choice of location? 148 (34) 284
Were you given a choice of Specialist? 87 (20) 348
Did you use information obtained from Fifth 
Sense?
134 (29) 330
Did you request a referral? 265 (54) 227
Were you offered a referral? 251 (53) 225
Was your case recognised as needing a 
referral?
274 (60) 185
Was your case declined by the local Clinical 
Commissioning Group (CCG) so your GP was 
unable to help you?
12 (4) 294
Has information provided by Fifth Sense 
helped you in your efforts to get medical 
advice?
223 (40) 339
Do you consider that your smell/taste 
disorder has affected your quality of life?
548 (98) 14
Have you suffered from anxiety or depression 
as a result of your smell disorder?
340 (61) 221
If yes to anxiety or depression, have you?
Taken any medication prescribed by your 
GP? (eg antidepressants, sedatives, 
anxiolytics)
102 (30) 238
Taken an over- the- counter medicine? 42 (12) 298
Taken an alternative medicine remedy? 75 (22) 265
Received counselling? 73 (21) 267
Do you think your ability to smell/taste 
has improved since you first encountered 
problems with it?
138 (27) 376
Do you feel that this is as a result of medical 
advice and/or treatment?
89 (20) 353
Do you feel that this is the result of a 
complementary therapy such as smell 
training?
59 (14) 354
TA B L E  1C   Survey responses (part 3)
Mean Range
How many appointments have you had in total with?
GPs 5.6 0- 150
ENT specialist 4.6 0- 75
Neurologist 0.9 0- 54
Private provider 1.6 0- 50
     |  7BALL et AL.
4  | DISCUSSION
4.1 | Key results
Our study serves to illustrate a number of significant issues faced by 
patients with chemosensory disorders. Firstly, a lack of recognition 
in the wider medical profession but still with 1 in 4 ENT specialists 
failing to convince their patients that they appreciated the impact 
of their olfactory disorder; this was even more noticeable in over 
half of neurologists encountered. In fact, it is evident that the ex-
perience of this patient group with neurologists was largely disap-
pointing. Secondly, knowledge of appropriate treatments is lacking 
thus leading to no treatment or to repeated ineffective treatments 
being applied. This was further exacerbated by participants express-
ing little satisfaction with the usefulness of the advice given. Thirdly, 
accessing a specialist consultation was a challenge with 1 in 4 report-
ing difficulty in getting a referral. Due to the paucity of specialists 
dedicated to chemosensory disorders, respondents reported signifi-
cant journeys and costs associated with that. Finally, mental health 
aspects of being affected by chemosensory disorders have been 
clearly highlighted and 15% reported taking prescribed medication 
for this, therefore, also emphasising an additional healthcare burden.
4.2 | Limitations
The survey will not have been seen by those who are not online or 
do not have access to the aforementioned social media. This is likely 
to have disproportionately affect the older generations. Due to the 
origin of the survey in the UK and with Fifth Sense being a UK- based 
charity, over two thirds of the respondents reflect their experience 
with the National Health Service setting in the UK. It is also possible 
that an unknown number of patients may have had a good response 
to treatment, but these cases will not be apparent if they are not 
Fifth Sense members or have chosen not to respond to the survey 
because they were happy with the outcome of their treatment. It 
may also be that the treatments applied were reasonable, but none-
theless proved ineffective in resolving or improving the olfactory 
disorder. The charity membership and survey respondents will also 
tend to be more likely to be those who have persistent symptoms 
and thus are more difficult to treat. That said, respondents are re-
flective of those in need and seeking care and attention and have 
been shown in our previous work to use NHS resources in other 
ways if their sensory loss(es) are not addressed.16 The survey also 
captured a retrospective perspective on those who had experienced 
difficulties with accessing healthcare.
The travel and cost issues demonstrated a significant spread of 
data; this may however reflect the small number of specialist cen-
tres seeing these patients and thus the distances and costs they 
face having to travel to them; the authors know of patients willing 
to travel to another continent for help and advice, even in countries 
with established health services free at the point of access.
Although the survey is based on self- reporting and no psycho-
physical testing has been performed, this obviously would not re-
flect the nature of the core problem facing these patients; they are 
unable to access a clinician and smell/taste testing in the first place. 
For any children participants, the responses will reflect the views of 
the parents/guardians rather than the child.
4.3 | Interpretation
The demographics and aetiology of study participants were in keep-
ing with the typical female predominance seen in other studies 
and with sinonasal disease and post- viral olfactory loss as leading 
causes.21- 24 The study also underlines the mental health impact of 
previous studies in those with olfactory disorders.16,17,21 However, 
this study makes a clear reflection on the paucity of services pro-
vided to this patient group and shows that the relatively poor en-
gagement by the medical profession has changed little in nearly two 
decades.25 Our data would suggest this is clearly an issue in the UK 
healthcare setting, but international responses also suggest this is 
potentially a global issue with little emphasis placed on either the 
importance of these senses in everyday life or the consequences of 
losing them.
4.4 | Generalisability
There is an unmet need for patients with olfactory disorders in 
accessing healthcare including engagement from the medical pro-
fession and signposting to appropriate information and treatment 
options.26 It remains to be seen as to whether the current wave of 
COVID- 19- related smell loss as a result of the global pandemic will 
give rise to an increase in patients presenting with post- viral olfac-
tory loss but with an estimated rate of anosmia globally of 5% and 
hyposmia up to 20%, these disorders are common and engagement 
from the medical profession is not matching this. This underlines 
the raison d'être of Fifth Sense which amongst its strategic aims is 
the need to improve education of the role of these senses in eve-
ryday life as well as providing support for those affected by these 
disorders. To move this forward, Fifth Sense plans to work with the 
medical profession to not only provide patient support, but also 
to work with the wider body of stakeholders that need to be en-
gaged in improving the current situation faced by these patients 
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in accessing suitable care, including appropriate psychological sup-
port. As part of this initiative, Fifth Sense is leading the James Lind 
Alliance Priority Setting Partnership to determine what should be 
the top ten research priorities for those with smell and taste dis-
orders https://www.jla.nihr.ac.uk/prior ity- setti ng- partn ershi ps/
smell - and- taste - disor ders/.
REPORTING GUIDELINE S
This study has been reported in line with the Strobe guidelines (see 
Appendix 2).
DATA AVAIL ABILIT Y S TATEMENT
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APPENDIX 1
Introductory statement provided to participants
Fifth Sense is launching a survey to capture patients' experiences of navigating the healthcare system. We know that so many of you face real 
challenges in getting support, advice or treatment from your doctors, although there are success stories too. The survey has been designed to 
capture data that will highlight both these challenges and successes as part of our ongoing efforts to improve awareness amongst the medical 
profession and improve patient experience.
We believe that this is the first piece of research to focus specifically on this issue and we're very proud to be part of a multidisciplinary 
project team. Supported by a grant from Newcastle Medical School, Fifth Sense have partnered with Mr Sean Carrie and Stephen Ball from 
Newcastle Freeman Hospital and Newcastle University and Olfactory Mapmaker Kate McLean and her colleague Rachel Hancock. An event 
in Newcastle in November 2018 brought together Fifth Sense and Voice North members to share experiences and help with the design of the 
survey. Kate and Rachel made drawings that captured the issues discussed and asked guests to complete “smell wheels” to visually represent 
their own smell experiences.
The results of the survey will be used to:
1. Inform Fifth Sense's ongoing efforts to raise awareness of smell and taste disorders amongst the medical profession and the need 
for widespread education/training for healthcare professionals
2. Help us develop information aimed at both patients and healthcare professionals to help ensure that patients have the best possible experi-
ence when seeking medical advice
3. Help future efforts to improve the patient journey through the healthcare system for people with a smell/taste disorder
4. Provide data to support applications future research studies and projects
5. Kate and Rachel are designing a poster to accompany the results which will visually represent some of the challenges faced by patients
6. The results will be published in an appropriate medical journal and on the Fifth Sense website.
The survey is completely anonymous and should take no longer than 10- 15 minutes to complete. It is based on the UK healthcare system, 
but it should still be relevant if you are based in another country. We would like contributions from people outside the UK as this data may help 
to show that this is a global issue. We'd also like to hear from parents of a child with a smell/taste disorder who have sought medical advice as 
it's important that your voices are heard too.
APPENDIX 2
STROBE Statement— checklist of items that should be included in reports of observational studies
Item No Recommendation Page
Title and abstract 1 (a) Indicate the study's design with a commonly used term in the title or the abstract 1






2 Explain the scientific background and rationale for the investigation being reported 2
Objectives 3 State specific objectives, including any prespecified hypotheses 3
Methods
Study design 4 Present key elements of study design early in the paper 3
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, 
follow- up, and data collection
4
Participants 6 (a) Cohort study— Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow- up
Case- control study— Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and controls
Cross- sectional study— Give the eligibility criteria, and the sources and methods of selection of 
participants
4
(b) Cohort study— For matched studies, give matching criteria and number of exposed and 
unexposed
Case- control study— For matched studies, give matching criteria and the number of controls per case
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Item No Recommendation Page
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. 




8* For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one group
4
Bias 9 Describe any efforts to address potential sources of bias 4
Study size 10 Explain how the study size was arrived at 5
Quantitative 
variables
11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
groupings were chosen and why
N/A
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 5
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study— If applicable, explain how loss to follow- up was addressed
Case- control study— If applicable, explain how matching of cases and controls was addressed
Cross- sectional study— If applicable, describe analytical methods taking account of sampling 
strategy
(e) Describe any sensitivity analyses
Results
Participants 13* (a) Report numbers of individuals at each stage of study— eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow- up, and 
analysed
5
(b) Give reasons for non- participation at each stage
(c) Consider use of a flow diagram
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on 
exposures and potential confounders
5
(b) Indicate number of participants with missing data for each variable of interest
(c) Cohort study— Summarise follow- up time (eg, average and total amount)
Outcome data 15* Cohort study— Report numbers of outcome events or summary measures over time N/A
Case- control study— Report numbers in each exposure category, or summary measures of 
exposure
Cross- sectional study— Report numbers of outcome events or summary measures
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their 
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and 
why they were included
5- 7
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful 
time period
Other analyses 17 Report other analyses done— eg analyses of subgroups and interactions, and sensitivity analyses N/A
Discussion
Key results 18 Summarise key results with reference to study objectives 8
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any potential bias
9
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant evidence
10
Generalisability 21 Discuss the generalisability (external validity) of the study results 10
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for 
the original study on which the present article is based
11
